Short- and Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome

  • Christian Hobeika
  • François Cauchy
  • Nicolas Poté
  • Pierre-Emmanuel Rautou
  • François Durand
  • Olivier Farges
  • Safi Dokmak
  • Valérie Vilgrain
  • Maxime Ronot
  • Valérie Paradis
  • Olivier SoubraneEmail author



While the metabolic syndrome (MS) is being recognized as an important risk factor for intrahepatic cholangiocarcinoma (ICC), the outcomes of liver resection in this context remain poorly described. This study aims to report the short- and long-term results of hepatectomy for patients with MS as risk factor for the development of ICC (MS+).


All patients undergoing hepatectomy for ICC between 2000 and 2016 at a single center were retrospectively analyzed. The perioperative outcomes of MS+ and ICC patients without MS (MS−) were compared.


Among 115 resected ICC patients, 40 (34.8%) were MS+ and 75 (65.2%) were MS−. MS+ exhibited an increased Charlson comorbidity index (5 ± 2 vs. 2 ± 2, p < 0.001) than MS− patients. While operative characteristics did not differ significantly between the 2 groups, MS+ experienced higher rate of major complications (62.5 vs. 29.3%, p = 0.001). On multivariate analysis, MS+ was an independent risk factor of major complication (HR 2.86, 95% CI 1.07–7.60, p = 0.036) and major cardiorespiratory complication (HR 4.35, 95% CI 1.50–12.62, p = 0.007). Pathological analysis revealed that MS+ displayed higher rates of non-alcoholic fatty liver disease (60.0 vs. 31.1%, p = 0.003) and non-alcoholic steatohepatitis (25 vs. 5.4%, p = 0.005). MS+ was independently associated with decreased risk of recurrence (HR 0.47, 95% CI 0.26–0.85, p = 0.001).


MS+ accounts for 35% of resected ICC patients. The existence of significant cardiovascular comorbidities increases postoperative morbidity and requires specific management.


Compliance with ethical standards

Conflict of interest

None of the authors have any conflict of interest of any kind.

Supplementary material

268_2019_4996_MOESM1_ESM.docx (32 kb)
Supplementary material 1 (DOCX 31 kb)
Supplementary material 2 (TIFF 63 kb)
Supplementary material 3 (TIFF 59 kb)


  1. 1.
    McCullough AJ (2011) Epidemiology of the metabolic syndrome in the USA. J Dig Dis 12(5):333–340CrossRefGoogle Scholar
  2. 2.
    Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K et al (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143(10):722–728CrossRefGoogle Scholar
  3. 3.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625–1638CrossRefGoogle Scholar
  4. 4.
    Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A et al (2013) Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer 108(1):222–228CrossRefGoogle Scholar
  5. 5.
    Nishioka T, Kubo S, Tanaka S, Wakasa K, Takemura S, Kinoshita M et al (2016) Outcomes of hepatic resection in intrahepatic cholangiocarcinoma patients with diabetes, hypertension, and dyslipidemia: significance of routine follow-up. Liver Cancer 5(2):107–120CrossRefGoogle Scholar
  6. 6.
    Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA (2011) Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatol Baltim Md 54(2):463–471CrossRefGoogle Scholar
  7. 7.
    Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V et al (2009) Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatol Baltim Md 49(3):851–859CrossRefGoogle Scholar
  8. 8.
    Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31(4):339–346CrossRefGoogle Scholar
  9. 9.
    Karagozian R, Derdák Z, Baffy G (2014) Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism 63(5):607–617CrossRefGoogle Scholar
  10. 10.
    Cauchy F, Zalinski S, Dokmak S, Fuks D, Farges O, Castera L et al (2013) Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg 100(1):113–121CrossRefGoogle Scholar
  11. 11.
    Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005) Cholangiocarcinoma. Lancet Lond Engl 366(9493):1303–1314CrossRefGoogle Scholar
  12. 12.
    Khan SA, Toledano MB, Taylor-Robinson SD (2008) Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB 10(2):77–82CrossRefGoogle Scholar
  13. 13.
    Palmer WC, Patel T (2012) Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 57(1):69–76CrossRefGoogle Scholar
  14. 14.
    Kinoshita M, Kubo S, Tanaka S, Takemura S, Nishioka T, Hamano G et al (2016) The association between non-alcoholic steatohepatitis and intrahepatic cholangiocarcinoma: a hospital based case-control study. J Surg Oncol 113(7):779–783CrossRefGoogle Scholar
  15. 15.
    Reddy SK, Hyder O, Marsh JW, Sotiropoulos GC, Paul A, Alexandrescu S et al (2013) Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg 17(4):748–755CrossRefGoogle Scholar
  16. 16.
    Viganò L, Conci S, Cescon M, Fava C, Capelli P, D’Errico A et al (2015) Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC. J Hepatol 63(1):93–101CrossRefGoogle Scholar
  17. 17.
    Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645CrossRefGoogle Scholar
  18. 18.
    Starley BQ, Calcagno CJ, Harrison SA (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatol Baltim Md 51(5):1820–1832CrossRefGoogle Scholar
  19. 19.
    Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey J-N, Mahvi D (2006) Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13(10):1271–1280CrossRefGoogle Scholar
  20. 20.
    Pang YY (2000) The Brisbane 2000 terminology of liver anatomy and resections. HPB 2:333–339 (HPB. 2002;4(2):99; author reply 99–100) CrossRefGoogle Scholar
  21. 21.
    Jones RM, Moulton CE, Hardy KJ (1998) Central venous pressure and its effect on blood loss during liver resection. Br J Surg 85(8):1058–1060CrossRefGoogle Scholar
  22. 22.
    Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D et al (2005) The «50–50 criteria» on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 242(6):824–828 (discussion 828–829) CrossRefGoogle Scholar
  23. 23.
    Ishizawa T, Hasegawa K, Kokudo N, Sano K, Imamura H, Beck Y et al (2009) Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma. Arch Surg Chic Ill 1960 144(1):46–51Google Scholar
  24. 24.
    Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L et al (2011) Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery 149(5):680–688CrossRefGoogle Scholar
  25. 25.
    Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG (1992) CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Am J Infect Control 20(5):271–274CrossRefGoogle Scholar
  26. 26.
    Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213CrossRefGoogle Scholar
  27. 27.
    Slankamenac K, Graf R, Barkun J, Puhan MA, Clavien P-A (2013) The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg 258(1):1–7CrossRefGoogle Scholar
  28. 28.
    WHO classification of tumours of the digestive system, 4th edn-WHO-OMS. Disponible sur:
  29. 29.
    AJCC Cancer Staging Manual|Mahul B. Amin|Springer. Disponible sur:
  30. 30.
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatol Baltim Md 41(6):1313–1321CrossRefGoogle Scholar
  31. 31.
    Bedossa P, Poitou C, Veyrie N, Bouillot J-L, Basdevant A, Paradis V et al (2012) Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatol Baltim Md 56(5):1751–1759CrossRefGoogle Scholar
  32. 32.
    Bedossa P, FLIP Pathology Consortium (2014) Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatol Baltim Md 60(2):565–575CrossRefGoogle Scholar
  33. 33.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefGoogle Scholar
  34. 34.
    Margini C, Dufour JF (2016) The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int 36(3):317–324CrossRefGoogle Scholar
  35. 35.
    Wong VW-S, Wong GL-H, Yip GW-K, Lo AO-S, Limquiaco J, Chu WC-W et al (2011) Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 60(12):1721–1727CrossRefGoogle Scholar
  36. 36.
    Bhayani NH, Hyder O, Frederick W, Schulick RD, Wolgang CL, Hirose K et al (2012) Effect of metabolic syndrome on perioperative outcomes after liver surgery: a National Surgical Quality Improvement Program (NSQIP) analysis. Surgery 152(2):218–226CrossRefGoogle Scholar
  37. 37.
    Mathur AK, Ghaferi AA, Sell K, Sonnenday CJ, Englesbe MJ, Welling TH (2010) Influence of body mass index on complications and oncologic outcomes following hepatectomy for malignancy. J Gastrointest Surg 14(5):849–857CrossRefGoogle Scholar
  38. 38.
    Nobili C, Marzano E, Oussoultzoglou E, Rosso E, Addeo P, Bachellier P et al (2012) Multivariate analysis of risk factors for pulmonary complications after hepatic resection. Ann Surg 255(3):540–550CrossRefGoogle Scholar
  39. 39.
    Kwok R, Choi KC, Wong GL-H, Zhang Y, Chan HL-Y, Luk AO-Y et al (2016) Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 65(8):1359–1368CrossRefGoogle Scholar
  40. 40.
    Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D et al (2008) Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 248(1):84–96CrossRefGoogle Scholar
  41. 41.
    Zhang X-F, Bagante F, Chakedis J, Moris D, Beal EW, Weiss M et al (2017) Perioperative and long-term outcome for intrahepatic cholangiocarcinoma: impact of major versus minor hepatectomy. J Gastrointest Surg 21(11):1841–1850CrossRefGoogle Scholar
  42. 42.
    Cai X, Liang X, Yu T, Liang Y, Jing R, Jiang W et al (2015) Liver cirrhosis grading Child-Pugh class B: a Goliath to challenge in laparoscopic liver resection?-prior experience and matched comparisons. Hepatobiliary Surg Nutr 4(6):391–397Google Scholar
  43. 43.
    Han K, Ko HK, Kim KW, Won HJ, Shin YM, Kim PN (2015) Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol 26(7):943–948CrossRefGoogle Scholar
  44. 44.
    Fujita N, Asayama Y, Nishie A, Ishigami K, Ushijima Y, Takayama Y et al (2017) Mass-forming intrahepatic cholangiocarcinoma: enhancement patterns in the arterial phase of dynamic hepatic CT—correlation with clinicopathological findings. Eur Radiol 27(2):498–506CrossRefGoogle Scholar
  45. 45.
    Aishima S, Iguchi T, Nishihara Y, Fujita N, Taguchi K, Taketomi A et al (2009) Decreased intratumoral arteries reflect portal tract destruction and aggressive characteristics in intrahepatic cholangiocarcinoma. Histopathology 54(4):452–461CrossRefGoogle Scholar
  46. 46.
    Bagante F, Spolverato G, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L et al (2017) Assessment of the lymph node status in patients undergoing liver resection for intrahepatic cholangiocarcinoma: the new eighth edition AJCC staging system. J Gastrointest Surg 22:52–59CrossRefGoogle Scholar
  47. 47.
    Türkoğlu MA, Yamamoto Y, Sugiura T, Okamura Y, Ito T, Ashida R et al (2016) The favorable prognosis after operative resection of hypervascular intrahepatic cholangiocarcinoma: a clinicopathologic and immunohistochemical study. Surgery 160(3):683–690CrossRefGoogle Scholar
  48. 48.
    Spolverato G, Yakoob MY, Kim Y, Alexandrescu S, Marques HP, Lamelas J et al (2015) Impact of complications on long-term survival after resection of intrahepatic cholangiocarcinoma. Cancer 121(16):2730–2739CrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2019

Authors and Affiliations

  • Christian Hobeika
    • 1
    • 2
    • 3
  • François Cauchy
    • 1
    • 2
    • 3
  • Nicolas Poté
    • 2
    • 3
    • 4
  • Pierre-Emmanuel Rautou
    • 2
    • 3
    • 5
  • François Durand
    • 2
    • 3
    • 5
  • Olivier Farges
    • 1
    • 2
    • 3
  • Safi Dokmak
    • 1
    • 2
    • 3
  • Valérie Vilgrain
    • 2
    • 3
    • 6
  • Maxime Ronot
    • 2
    • 3
    • 6
  • Valérie Paradis
    • 2
    • 3
    • 4
  • Olivier Soubrane
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of HPB Surgery and Liver TransplantationBeaujon HospitalClichyFrance
  2. 2.Assistance Publique Hôpitaux de ParisParisFrance
  3. 3.Université Paris VII Paris-DiderotParisFrance
  4. 4.Department of PathologyBeaujon HospitalClichyFrance
  5. 5.Department of HepatologyBeaujon HospitalClichyFrance
  6. 6.Department of RadiologyBeaujon HospitalClichyFrance

Personalised recommendations